genOway announces the creation of a joint venture in Shanghai (China), which will promote and sell locally its catalog of preclinical immuno-oncology models.

genOway's strategy through this joint venture is to develop a high-quality sales team able to deliver to its Chinese customers the same high scientific added value as that successfully provided on Western markets.

genOway will provide the joint venture with its immuno-oncology models and solutions, as well as the associated scientific and technical expertise.

genOway will hold 45% of the capital and have veto rights over the joint venture's strategic choices.

For their part, the joint venture's Chinese partners, from the MedTech field, will contribute their knowledge of the local market, their network and their ability to recruit and lead high-level scientific sales teams (PhD expert).

Copyright (c) 2023 CercleFinance.com. All rights reserved.